Remove

Doc description: Information Disclosure Statement (IDS) Filed Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number			10577887				
	Filing Date		2006-11-22				
	First Named Inventor	Baha	aa Botros Seedhorn				
	Art Unit		3775				
	Examiner Name	Larry	E. Waggle Jr.				
	Attorney Docket Number		7881 15				

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pate of cited Docu	entee or Applicant ment	Rele	es,Columns,Lines where want Passages or Releves res Appear	
	1	5632747	A	1997-05	i-27	SCARBOROU	GH et al.			
If you wisl	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.	-	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
		Kind Code ¹	d Publication Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	20030199879	A1	2003-10	1-23	SPRANZA, III				
If you wis	h to ad	d additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d butto	on. Add	
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove	
		Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TE
	1	2003-515384	JP			2003-05-07				
	2	2001-520911	JP			2001-11-06	Roland Jakob et al			
	3	10-513387	JP			1998-12-22	JAMES M. PACHE	NCE		

U.S. PATENTS

| INFORMATION DISCLOSURE | STATEMENT BY APPLICANT | (Not for submission under 37 CFR 1.99) | Art Unit | 1057/838 | 1057/838 | Filing Date | 2006-11-22 | Fil

		5	03/007805	wo		2003-01-30	DEPUY PRODUCTS, INC.			
		6	2001-516610	JP		2001-10-02	EDDY H. DEL RIO			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher city and/or country where publisher.								Ţ5	

2003-12-24

positives, say action country men's positives.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

wo

03/105700

Date Considered

BLUF PLANET

MEDICAL LTD.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16e Kind Code of USEPO Patent Documents at every USEPO_COLV or MEPE 90.04. 1 Educ or finds that issued the document, by the broketer code (WPO). Standard 513, 19 For Juprieses patent colourests, the ordinates or the year of the register control protection to evid unknown that the colourest or the year of the register control protection to evid unknown of the year of the register control protection to evid unknown of the year of the register control protection. If you protect the resident protection is the protection of the year of year of the year of year

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577887		
Filing Date		2006-11-22		
First Named Inventor	Bahaa Botros Seedhom			
Art Unit		3775		
Examiner Name Larry		E. Waggle Jr.		
Attorney Docket Number		7881.15		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s	s):
---------------	----------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Evan R. Witt/	Date (YYYY-MM-DD)	2011-08-22
Name/Print	Evan R. Witt	Registration Number	32,512

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.